同和药业(300636.SZ)：“甲苯磺酸艾多沙班”原料药通过CDE审批

Core Viewpoint - Tonghua Pharmaceutical (300636.SZ) has received approval from the National Medical Products Administration (NMPA) for its active pharmaceutical ingredient, tolvaptan, which is an oral anticoagulant used for preventing strokes and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment or prevention of deep vein thrombosis and pulmonary embolism [1] Group 1 - The company has recently confirmed the approval of its active pharmaceutical ingredient, tolvaptan, through the CDE's public platform [1] - Tolvaptan is primarily used for preventing strokes and systemic embolism in patients with non-valvular atrial fibrillation [1] - The drug is also indicated for the treatment or prevention of deep vein thrombosis and pulmonary embolism [1]